Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19

  1. Kazuo Imai
  2. Sakiko Tabata
  3. Mayu Ikeda
  4. Sakiko Noguchi
  5. Yutaro Kitagawa
  6. Masaru Matuoka
  7. Kazuyasu Miyoshi
  8. Norihito Tarumoto
  9. Jun Sakai
  10. Toshimitsu Ito
  11. Shigefumi Maesaki
  12. Kaku Tamura
  13. Takuya Maeda

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.jcv.2020.104393
  2. ScreenIT

    SciScore for 10.1101/2020.04.22.20075564: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Ethical statement: The study design and protocol were reviewed and approved by the Institutional Review Board of the Japan Self-Defense Forces Central Hospital (
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Detection of IgM and IgG antibodies for SARS-CoV2: IgM/IgG antibody tests for SARS-CoV2 were performed using the One Step Novel Coronavirus (COVID-19
    SARS-CoV2: IgM/IgG
    suggested: None
    The presence of only the control line indicates a negative result; the presence of both the control line and the IgM or IgG antibody line indicates a positive result for IgM or IgG antibody, respectively.
    IgG
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    A major limitation of this study was the low number of patients. In addition, only one commercial IC kit was evaluated. The commercial IC assay verified to have the best performance in the clinical setting should be chosen for further studies. Multicenter, multi-national, prospective studies are warranted to determine the usefulness of IC assays and chest CT for diagnosing COVID-19.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.04.22.20075564v1 on medRxiv